Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis

Christian Brandt; N Frimodt-Moller; Jens Dilling Lundgren; M Pedersen; IC Skovsted; Ian John Rowland; C Ostergaard

Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis

Christian Brandt, N Frimodt-Moller, Jens Dilling Lundgren, M Pedersen, IC Skovsted, Ian John Rowland, C Ostergaard

3 Citationer (Scopus)

Abstract

OBJECTIVE: Bacteraemia concomitant with meningitis has been shown to greatly affect outcome. Consequently, the efficacy of serotype-specific anti-pneumococcal antiserum (APAS) was investigated in a rat model of pneumococcal meningitis. METHODS: Rats were infected with Streptococcus pneumoniae serotype 3. All rats received ceftriaxone starting 26 h post-infection. APAS was administered either at the time of infection or 26 h post-infection and effects were compared with rats treated with antibiotics only. RESULTS AND CONCLUSION: A significant clinical benefit was found when APAS was given at the time of infection whereas no effect was found when administered 26 h after infection. This work indicates that the clinical value of using APAS in pneumococcal meningitis may be limited

Originalsprog	Engelsk
Tidsskrift	Journal of Antimicrobial Chemotherapy
Vol/bind	58
Udgave nummer	6
Sider (fra-til)	1291-4
ISSN	0305-7453
Status	Udgivet - 2006

Adgang til dokumentet

http://jac.oxfordjournals.org/cgi/content/full/58/6/1291

Citationsformater

@article{d9a4680a738c4f079c5ec4f98fda5cae,

title = "Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis",

abstract = "OBJECTIVE: Bacteraemia concomitant with meningitis has been shown to greatly affect outcome. Consequently, the efficacy of serotype-specific anti-pneumococcal antiserum (APAS) was investigated in a rat model of pneumococcal meningitis. METHODS: Rats were infected with Streptococcus pneumoniae serotype 3. All rats received ceftriaxone starting 26 h post-infection. APAS was administered either at the time of infection or 26 h post-infection and effects were compared with rats treated with antibiotics only. RESULTS AND CONCLUSION: A significant clinical benefit was found when APAS was given at the time of infection whereas no effect was found when administered 26 h after infection. This work indicates that the clinical value of using APAS in pneumococcal meningitis may be limited",

author = "Christian Brandt and N Frimodt-Moller and Lundgren, {Jens Dilling} and M Pedersen and IC Skovsted and Rowland, {Ian John} and C Ostergaard",

year = "2006",

language = "English",

volume = "58",

pages = "1291--4",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis

AU - Brandt, Christian

AU - Frimodt-Moller, N

AU - Lundgren, Jens Dilling

AU - Pedersen, M

AU - Skovsted, IC

AU - Rowland, Ian John

AU - Ostergaard, C

PY - 2006

Y1 - 2006

N2 - OBJECTIVE: Bacteraemia concomitant with meningitis has been shown to greatly affect outcome. Consequently, the efficacy of serotype-specific anti-pneumococcal antiserum (APAS) was investigated in a rat model of pneumococcal meningitis. METHODS: Rats were infected with Streptococcus pneumoniae serotype 3. All rats received ceftriaxone starting 26 h post-infection. APAS was administered either at the time of infection or 26 h post-infection and effects were compared with rats treated with antibiotics only. RESULTS AND CONCLUSION: A significant clinical benefit was found when APAS was given at the time of infection whereas no effect was found when administered 26 h after infection. This work indicates that the clinical value of using APAS in pneumococcal meningitis may be limited

AB - OBJECTIVE: Bacteraemia concomitant with meningitis has been shown to greatly affect outcome. Consequently, the efficacy of serotype-specific anti-pneumococcal antiserum (APAS) was investigated in a rat model of pneumococcal meningitis. METHODS: Rats were infected with Streptococcus pneumoniae serotype 3. All rats received ceftriaxone starting 26 h post-infection. APAS was administered either at the time of infection or 26 h post-infection and effects were compared with rats treated with antibiotics only. RESULTS AND CONCLUSION: A significant clinical benefit was found when APAS was given at the time of infection whereas no effect was found when administered 26 h after infection. This work indicates that the clinical value of using APAS in pneumococcal meningitis may be limited

M3 - Journal article

SN - 0305-7453

VL - 58

SP - 1291

EP - 1294

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 6

ER -

Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater